Stable Isotope-Labeled Synthetic Intermediates
Share
Deuterated Reagents for Pharmaceutical and Synthetic Applications
- Deuterated Reagents for Pharmaceutical and Synthetic Applications
Stable Isotope-Labeled Synthetic Intermediates
In recent years, some pharmaceutical companies have begun to investigate deuteration of molecules that may provide advantages over their existing nondeuterated counterparts. In addition, increasing research into the potential medical advantages of new deuterated drugs is also occurring.
The potential advantages of deuterated pharmaceuticals includes:
Improved metabolic profile. The improved metabolic profile may potentially reduce or eliminate unwanted side effects or undesirable drug interactions.
Improved oral bioavailability. Deuteration in some compounds has reduced the presystemic metabolism that occurs in the digestive track, allowing more of the unmetabolized drug to reach its target.
Increased half-life. Deuterated compounds can have a slower pharmacokinetic effect, extending the absorption and distribution in the body. This may decrease the number of doses a patient may require in a certain time period compared to its nondeuterated counterpart.
| Catalog No. | Description |
| DLM-112 | Acetaldehyde-d (D, 99%) |
| DLM-12RG* | Acetic acid-d4 (D, 99%) |
| DLM-1556 | Acetic acid-d (D, 98%) |
| DLM-1162 | Acetic anhydride-d6 (D, 98%) |
| DLM-9RG* | Acetone-d6 (D, 99.5%) |
| DLM-247 | Acetyl chloride-d3 (D, 98%) |
| DLM-855 | Acrylic-2,3,3,-d3 acid (+ 0.1% 4-methoxyphenol) (D, 98%) (<5% H2O) |
| DLM-710RG* |
Ammonium deuteroxide-d5 (D, 99%) (~25% sol. in D2O)
|
| DLM-862 | Aniline-ring-d5 (D, 98%) |
| DLM-1RG* | Benzene-d6 (D, 99%) |
| DLM-494 | Biphenyl- d10 (D, 98%) |
| DLM-1315 | Borane-d3, (D, 98%) (1 molar in THF) (+0.005M NaBD4) |
| DLM-4747 | Borane-d3 methylsulfide complex (D, 98%) (contains <10% additional dimethylsulfide) |
| DLM-398 | Bromobenzene-d5 (D, 99%) |
| DLM-874 | Bromoethane-d5 (D, 98%) |
| DLM-181 | 1,4-Butanediol-2,2,3,3-d4 (D, 98%) |
| DLM-1664 | tert-Butanol-d10 (D, 98%) |
| DLM-10515 | tert-Butyl-acetate-d9 (D, 98%) |
| DLM-1116 | tert-Butyl chloride-d9 (D, 98%) |
| DLM-263 | Chlorobenzene-d5 (D, 99%) |
| DLM-337 | Chloromethane-d3 (D, 99%) |
| DLM-7RG* | Chloroform-d (D, 99.7%) |
| DLM-1560 | Cyclohexanone-d10 (D, 98%) |
| DLM-2781 | Cyclopentyl bromide-d9 (D, 98%) |
| DLM-1003DR | Deuterium (D, 99.96) <400 ppm HD |
| DLM-408DR | Deuterium (D, 99.8%) (D2, 99.6% + HD, 0.4%) |
| DLM-458DR | Deuterium chloride (D, 99%) |
| DLM-3DR | Deuterium chloride (D, 99.5%) DCl 35% w/w solution in D2O |
| DLM-2 | Deuterium chloride (D, 99.5%) DCl 20% w/w solution in D2O |
| DLM-4DR | Deuterium oxide (D, 99.9%) |
| DLM-4DR-99.8 | Deuterium oxide (D, 99.8%) |
| DLM-195 | 1,2-Dibromoethane-d4 (D, 99%) |
| DLM-6020-1.2 | 1,2-Dibromopropane-d6 (D, 98%) |
| DLM-158 | 1,2-Dichlorobenzene-d4 (D, 99%) |
| DLM-265 |
Dimethyl-d6-amine:HCI (D,98%)
|
| DLM-3903 | Dimethyl carbonate-d6 (D, 99%) |
| DLM-196 | Dimethyl sulfate-d6 (D, 98%) |
| DLM-10RG* | Dimethyl sulfoxide-d6 (D, 99.9%) |
| DLM-25 | N,N-Dimethylformamide-d7 (D, 99.5%) |
| DLM-1670 | N,N Dimethylformamide (formyl-D, 98-99%) |
| DLM-31 | Ethanol-d6 (D, 99%) anhydrous |
| DLM-31RG* | Ethanol-d6 (D, 99%) 5-6% D2O |
| DLM-16 | Ethanol-OD (D, 99%) <6% D2O |
| DLM-9660 | N-Ethylaniline-d10 (D, 98%) |
| DLM-9626 | N-Ethyl-d5-aniline (D, 98%) |
| DLM-347 | Ethylene-d4 (D, 98%) |
| DLM-805 | Formaldehyde-d2 (D, 98%) (~20% w/w in D2O) |
| DLM-286 | Formic acid-d2 (D, 98%) (<5% D2O) |
| DLM-743 | Formic acid (formyl-D, 98%) (<5% H2O) |
| DLM-423 | n-Heptane-d16 (D, 98%) |
| DLM-1023 | Iodoethane-1,1-d2 (D, 98%) + copper wire |
| DLM-1024 | Iodoethane-2,2,2-d3 (D, 98%) + copper wire |
| DLM-272 | Iodoethane-d5 (D, 99%) + copper wire |
| DLM-44 | Isopropanol-d8 (D, 99%) |
| DLM-6201 | a-Ketoglutaric acid-3,3,4,4-d4 (D, 98%) CP 90 |
| DLM-1945 | bis(2-Chloroethoxy)-d8-methane (D, 98%) |
| DLM-1981 | Methanesulfonic acid-d4 (D, 97-98%) |
| DLM-24RG* | Methanol-d4 (D, 99.5%) |
| DLM-15 | Methanol-OD (D, 99%) |
| DLM-10186 |
Methylboronic acid (methyl-D3, 98%) > 90% CP
|
| DLM-651 | Methyl formate (formyl-D, 99%) |
| DLM-362 | Methyl iodide-d3 (D, 99.5%) + copper wire |
| DLM-9707 | Methyl-d3 methanesulfonate (D, 98%) |
| DLM-1500DR | Methyl-d3-amine (D, 98%) |
| DLM-289 | Methyl-d3-amine·HCl (D, 98%) |
| DLM-23RG* | Methylene chloride-d2 (D,99.8%) |
| DLM-3484 | Morpholine-2,2,3,3,5,5,6,6-d8 (D, 98%) |
| DLM-295 | 2-Nitrophenol-ring-d4 (D, 98%) |
| DLM-296 | 4-Nitrophenol-ring-d4 (D,98%) |
| DLM-619 | Octanoic acid-d15 (D, 98%) |
| DLM-300 | Paraformaldehyde-d2 (D, 99%) |
| DLM-370 | Phenol-d6 (D, 98%) |
| DLM-788 | Phthalic anhydride-d4 (D, 98%) |
| DLM-9813 | Pivalic acid-trimethyl-d9, (D, 98%) |
| DLM-9662 | Pyrrolidine-2,2,3,3,4,4,5,5-d8 (D, 98%) |
| DLM-3078DR | N-Propanol-d7 (D, 98%) |
| DLM-226 | Sodium borodeuteride-d4 (D, 99%) CP 90-95% |
| DLM-45DR | Sodium deuteroxide (D, 99.5%) 40% in D2O |
| DLM-1361 | Sodium formate (D, 98%) |
| DLM-8206 | Sodium 2,2-dimethyl-2silapentane-5-sulfonate-d6 (DSS) (D, 98%) |
| DLM-33DR | Sulfuric acid-d2 (D, 99%) 96-98% in D2O |
| DLM-36 | Tetrahydrofuran-d8 (D, 99.5%) |
| DLM-2729 | Tetramethylsilane-d12 (D, 98%) |
| DLM-5RG* | Toluene-d8 (D, 99.5%) |
| DLM-46RG* |
Trifluoroacetic acid-d (D. 98%)
|
*Reagent grade
CP = chemical purity
Frequently Asked Questions
What do I do if I need multiple vials or carboys when returning D2O for the D2O Recovery Program?
If you have more than ~16 L you may require multiple carboys, please just ask.
When returning D2O for the D2O Recovery Program should I fill the carboy to the top?
No! Fill the bulk carboy container ~80% full. Most are shipped by FedEx Air, and if full, the carboy is likely to expand and possibly rupture the container.
References
Falb, E.; Ulanenko, K.; Tor, A.; et al. 2017. A highly efficient Suzuki-Miyaura methylation of pyridines leading to the drug pirfenidone and its CD3 version (SD-560). Green Chemistry, 21. Read article
Pepper Hamilton LLP. 2017. Deuterated drugs are new chemical entities. JDSUPRA® Read more
Mullard, A. 2016. Deuterated drugs draw heavier backing. Nat Rev Drug Discov, 15(4), 219-221. PMID: 27032821
2015. Drugs that live long will prosper. The Economist, Science & Technology, Sept. 5 edition. economist.com. Read article
Tung, R. 2010. The development of deuterium-containing drugs. Innovations Pharm Technol, 32(32), 24-28. Read article
.jpg)
Tasha Agreste
Deuterated Reagents & Intermediates Product Manager, China Sales – Research Products
Tasha Agreste currently holds the position of Deuterated Reagents and Intermediates Product Manager, where she focuses her time working with companies on their stable isotope-labeled product needs for synthetic applications, including the manufacturing of APIs.
More
